Johnson & Johnson (J&J) on Monday said that the US Food and Drug Administration (USFDA) approved the company's psoriasis drug 'Stelara', for use in adults with Crohn's disease. The drug is one of J&J's largest revenue generators, with sales of about $2.5 billion in 2015. Notably, the disease affects about 700,000 Americans and nearly 250,000 Europeans, the company stated.